Valencian Community Doubles Biosimilar Market Penetration

Biosimilars accounted for 15% of the Valencian market in 2015. “They are now almost double, around 27%” said Patricia Lacruz, leading to €900,000 in savings, ” in addition to promoting competition and that branded biologicals have had to reduce their prices”.

Valencia has 3 core pillars for its pharmaceutical policies:

  1. promotion of biosimilar drugs
  2. central purchasing
  3. replacement algorithms for prescriptions

These policies help improve efficiency and cut costs.

Fore more information, click here.

Tagged with

Published 3. March 2017 in News Spain